Nurix Therapeutics, Inc. - NRIX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G | Vestal Point Capital, LP | 6.3% | 6,500,000 | View |
| May 15, 2026 | SCHEDULE 13G | Ryan Wilder | 6.3% | 6,500,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 6.17% | 6,345,244 | View |
| May 15, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 6.17% | 6,345,244 | View |
| May 15, 2026 | SCHEDULE 13G/A | David Kroin | 6.17% | 6,345,244 | View |
| May 06, 2026 | SCHEDULE 13G | FMR LLC | 5.4% | 5,541,271 | View |
| May 06, 2026 | SCHEDULE 13G | Abigail P. Johnson | 5.4% | 5,541,271 | View |
| Apr 24, 2026 | SCHEDULE 13G/A | Redmile Group, LLC | 9.9% | 10,696,314 | View |
| Apr 24, 2026 | SCHEDULE 13G/A | Jeremy C. Green | 9.9% | 10,696,314 | View |
| Apr 24, 2026 | SCHEDULE 13G/A | RedCo II Offshore SPV LLC | 5.6% | 5,967,424 | View |
| Apr 24, 2026 | SCHEDULE 13G/A | RedCo II Master Fund, L.P. | 0.0% | 0 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Baker Bros. Advisors LP | 7.2% | 7,527,996 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Baker Bros. Advisors (GP) LLC | 7.2% | 7,527,996 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Julian C. Baker | 7.2% | 7,527,996 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Felix J. Baker | 7.2% | 7,527,996 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.